This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Worth Repeating: Vertex Is the Next Gilead Sciences

Vertex cystic fibrosis revenue of $6-7 billion year is equal to what Gilead generates in revenue every year from is antiviral product sales, mostly its dominant HIV drugs.

Comparing Vertex to Gilead is very appropriate because their respective revenue streams are sticky, like an annuity delivered every year without fail. Think about it, a cystic fibrosis patient with the f508del mutation will start therapy on Vertex's VX-809 and Kalydeco as a child and will continue on therapy for their rest of their life. Vertex has no competition on the near horizon and its patents extend out to 2027.

This is exactly how Gilead grew to be a monster stock in biotech. Patients take Gilead's Truvada or Atripla to keep the virus in check and they continue taking these drugs day after day, year after year. If anything, Gilead's position is a bit more tenuous compared to Vertex because competitive HIV drugs from other companies exist and Gilead's patent position is weaker.

With Monday's big stock surge, Vertex carries a market cap of $11.5 billion, still well below Gilead even if you subtract the value attached to its recent push into hepatitis C.

If you think comparing Vertex to Gilead isn't appropriate, then how about Alexion and its orphan disease drug Soliris, which is currently on a $1 billion sales run rate and growing like gangbusters. Alexion is a $17 billion company, but Vertex is only worth $11.5 billion?

These market value comparisons are imprecise, granted, but you get the idea. Don't under-estimate the sheer size of Vertex's revenue potential in cystic fibrosis or its durability. [I'm not even considering Vertex's still very much alive hepatitis C business, either.] This is why investors have come to love and covet the stock of companies developing truly effective therapies for rare, genetic diseases.

Big Pharma loves rare disease companies, too. Sanofi (SNY) bought Genzyme for $20 billion, remember? It's hard to imagine a company like Johnson & Johnson (JNJ) not running the numbers right now on buying Vertex. Speculating on a takeout is not reason enough to own a stock, but in the case of Vertex, the huge commercial potential for its cystic fibrosis business is compelling even without an acquisition.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALXN $180.28 1.03%
GILD $105.85 -0.10%
VRTX $130.36 0.77%
AAPL $117.34 -0.81%
FB $107.12 2.76%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs